NFKB1 and myeloid sarcoma: Finally, the therapeutic mechanism of dimethyl fumarate, which is approved for MS management, has been shown to correlate with a dramatic reduction in proinflammatory B cell subsets in vitro partially due to the inhibition of NF-κB activation (81).